{"ticker": {"uuid": "4462d582-ffa0-4ad8-8e28-dc0a53589a12", "symbol": "INSM", "name": "Insmed Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Is Insmed (INSM) Undervalued After Positive TPIP Data Backed A Phase 3 Push?", "summary": "Insmed (INSM) shares are in focus following positive 12-month data from an open-label extension study for treprostinil palmitil inhalation powder in pulmonary arterial hypertension. Despite recent share price volatility, analysts suggest Insmed is significantly undervalued, with ", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-insm/insmed/news/is-insmed-insm-undervalued-after-positive-tpip-data-backed-a/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-20T02:11:22", "published_display": "20 Jul 2026 02:11", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insmed (INSM) Reports 12 Month TPIP Data That Sets Up Phase 3", "summary": "Insmed has reported positive 12-month open-label extension data for TPIP in pulmonary arterial hypertension, showing sustained improvements in clinical endpoints with no new safety signals. These results pave the way for a Phase 3 randomized, controlled trial, providing a new dat", "url": "https://www.webull.com/news/15249917983138816", "source_name": "Webull", "published_at": "2026-07-19T08:11:22", "published_display": "19 Jul 2026 08:11", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Quick Look at Today's Ratings for Insmed(INSM.US), With a Forecast Between $161 to $237", "summary": "This article provides an overview of recent analyst ratings for Insmed (INSM.US), highlighting a consensus price target range of $161 to $237. It outlines the bullish sentiment surrounding the stock based on these expert evaluations. The information suggests a positive outlook fo", "url": "https://www.moomoo.com/news/post/73147296/a-quick-look-at-today-s-ratings-for-insmed-insmus", "source_name": "Moomoo", "published_at": "2026-07-17T15:39:37", "published_display": "17 Jul 2026 15:39", "sentiment": "positive", "sentiment_pct": 76, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insmed stock price target maintained at $200 by Stifel on trial data", "summary": "Stifel reiterated a Buy rating and a $200 price target for Insmed (NASDAQ:INSM) after the company released 12-month open-label extension data from its Phase 2b trial for TPIP, a pulmonary arterial hypertension treatment candidate. The data showed continued clinical benefit and re", "url": "https://www.investing.com/news/analyst-ratings/insmed-stock-price-target-maintained-at-200-by-stifel-on-trial-data-93CH-4798328", "source_name": "Investing.com", "published_at": "2026-07-17T12:10:44", "published_display": "17 Jul 2026 12:10", "sentiment": "positive", "sentiment_pct": 76, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insmed moves closer to $6B opportunity as PAH drug shows long-term durability", "summary": "Insmed's investigational pulmonary arterial hypertension (PAH) drug, treprostinil palmitil inhalation powder (TPIP), demonstrated \"impressive\" long-term efficacy and biomarker improvements in an open-label extension study. Guggenheim Partners projects peak TPIP sales to exceed $6", "url": "https://www.biospace.com/drug-development/insmed-moves-closer-to-6b-opportunity-as-pah-drug-shows-long-term-durability", "source_name": "BioSpace", "published_at": "2026-07-17T12:10:44", "published_display": "17 Jul 2026 12:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insmed Says Treprostinil Shows Sustained Benefit to Pulmonary Arterial Hypertension Patients", "summary": "Insmed announced that data from their Phase 1 TREMOLOTM and Phase 2 BEATTM studies indicate that treprostinil showed sustained benefits for pulmonary arterial hypertension (PAH) patients. The data suggests that the drug could improve pulmonary vascular hemodynamics, functional ca", "url": "https://www.moomoo.com/news/post/73074851/insmed-says-treprostinil-shows-sustained-benefit-to-pulmonary-arterial-hypertension", "source_name": "Moomoo", "published_at": "2026-07-17T08:11:22", "published_display": "17 Jul 2026 08:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insmed reports 12-month TPIP data in pulmonary arterial hypertension", "summary": "Insmed has released positive 12-month data from an ongoing open-label extension study of treprostinil palmitil inhalation powder (TPIP) for pulmonary arterial hypertension (PAH). The data showed sustained improvements in functional, biomarker, and risk-status measures in PAH pati", "url": "https://www.biospectrumasia.com/news/89/28051/insmed-reports-12-month-tpip-data-in-pulmonary-arterial-hypertension.html", "source_name": "BioSpectrum Asia", "published_at": "2026-07-17T08:10:44", "published_display": "17 Jul 2026 08:10", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insmed Incorporated (INSM) Discusses 12-Month Results From Ongoing TPIP Open-Label Extension Study in PAH Patients - Slideshow (NASDAQ:INSM)", "summary": "Insmed Incorporated (INSM) has released a slide deck detailing the 12-month results from its ongoing open-label extension study of TPIP in patients with Pulmonary Arterial Hypertension (PAH). This information was published in conjunction with an event. The study's findings are pr", "url": "https://seekingalpha.com/article/4922780-insmed-incorporated-insm-discusses-12-month-results-from-ongoing-tpip-open-label-extension", "source_name": "Seeking Alpha", "published_at": "2026-07-16T20:27:00", "published_display": "16 Jul 2026 20:27", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Insmed Announces Positive 12-Month Data from the Ongoing Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Patients with Pulmonary Arterial Hypertension", "summary": "Insmed announced positive 12-month data from its open-label extension study of treprostinil palmitil inhalation powder (TPIP) for pulmonary arterial hypertension (PAH). The data showed sustained improvement in efficacy measures, including a reduction in mortality risk, and TPIP w", "url": "https://investor.insmed.com/2026-07-16-Insmed-Announces-Positive-12-Month-Data-from-the-Ongoing-Open-Label-Extension-Study-of-Treprostinil-Palmitil-Inhalation-Powder-TPIP-in-Patients-with-Pulmonary-Arterial-Hypertension", "source_name": "Insmed Incorporated Investor Relations", "published_at": "2026-07-16T19:10:44", "published_display": "16 Jul 2026 19:10", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insmed's TPIP Shows Durable PAH Benefits in 12-Month Study", "summary": "", "url": "https://finance.yahoo.com/m/3ab1f69d-9a5a-3c69-98ca-513a4db1c11c/insmed%27s-tpip-shows-durable.html", "source_name": "MarketBeat", "published_at": "2026-07-16T15:04:50+00:00", "published_display": "16 Jul 2026 15:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insmed reports 12-month data for PAH treatment candidate", "summary": "Insmed (NASDAQ:INSM) announced positive 12-month open-label extension study data for its treprostinil palmitil inhalation powder (TPIP) in patients with pulmonary arterial hypertension (PAH). Patients showed significant improvement in six-minute walk distance and decreased NT-pro", "url": "https://www.investing.com/news/company-news/insmed-reports-12month-data-for-pah-treatment-candidate-93CH-4795424", "source_name": "Investing.com", "published_at": "2026-07-16T11:42:31", "published_display": "16 Jul 2026 11:42", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insmed reports positive 12-month OLE results for TPIP showing sustained 6MWD, ~60% NT-proBNP drop", "summary": "Insmed announced positive 12-month Open-Label Extension (OLE) results for TPIP, demonstrating sustained efficacy and good tolerability. The study showed a mean 6MWD improvement in both continued and placebo-crossed groups, aligning by Month 12, along with a significant ~60% drop ", "url": "https://www.tradingview.com/news/tradingview:7718dcb8df0c2:0-insmed-reports-positive-12-month-ole-results-for-tpip-showing-sustained-6mwd-60-nt-probnp-drop/", "source_name": "TradingView", "published_at": "2026-07-16T10:42:31", "published_display": "16 Jul 2026 10:42", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "William Haggerty Joins Insmed Incorporated as Senior Director of People Operations", "summary": "Insmed Incorporated has appointed William Haggerty as Senior Director of People Operations. With over two decades of experience in HR transformation, talent strategy, and AI-enabled workforce innovation, Haggerty previously served at IBM where he spearheaded AI-powered talent ini", "url": "https://hrtoday.in/william-haggerty-joins-insmed-incorporated-as-senior-director-of-people-operations/", "source_name": "https://hrtoday.in/", "published_at": "2026-07-14T17:35:56", "published_display": "14 Jul 2026 17:35", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insmed (INSM) After Insider Selling And Brensocatib Hopes What Does Valuation Say", "summary": "Insmed (INSM) is under scrutiny after its Chair and CEO sold shares following the exercise of stock options. Despite a year-to-date share price drop, longer-term holders have seen significant gains. The article explores Insmed's valuation, highlighting a narrative suggesting it's", "url": "https://www.sahmcapital.com/news/content/insmed-insm-after-insider-selling-and-brensocatib-hopes-what-does-valuation-say-2026-07-13", "source_name": "Sahm", "published_at": "2026-07-13T18:39:56", "published_display": "13 Jul 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Enterprise value to EBIT forward of Insmed Incorporated \u2013 BMV:INSM", "summary": "This article provides financial data for Insmed Incorporated (BMV:INSM), focusing on its enterprise value to EBIT forward. It displays the company's financial overview on TradingView, indicating that the market was closed at the time of publication with no trades. The content pri", "url": "https://www.tradingview.com/symbols/BMV-INSM/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-12T08:41:21", "published_display": "12 Jul 2026 08:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Insmed Inc For: 10 July By Investing.com", "summary": "This article from Investing.com reports on a Form 4 filing for Insmed Inc. The filing was made on July 10, 2026. The article primarily consists of financial market data and navigation, with the core content being the brief announcement of the Form 4.", "url": "https://za.investing.com/news/stock-market-news/form-4-insmed-inc-for-10-july-93CH-4364859", "source_name": "Investing.com South Africa", "published_at": "2026-07-10T21:09:51", "published_display": "10 Jul 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insmed CEO William Lewis sells over $1.25m in company stock", "summary": "Insmed CEO William Lewis sold 10,699 shares of the company's common stock for over $1.25 million on July 9, 2026, while concurrently acquiring the same number of shares through stock option exercises. These transactions were executed under a Rule 10b5-1 trading plan. The company'", "url": "https://ng.investing.com/news/stock-market-news/insmed-ceo-william-lewis-sells-over-125m-in-company-stock-93CH-2595435", "source_name": "Investing.com Nigeria", "published_at": "2026-07-10T21:09:51", "published_display": "10 Jul 2026 21:09", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insmed Insider Sold Shares Worth $1,256,084, According to a Recent SEC Filing", "summary": "Insmed insider Paul C. Chapman sold 37,294 shares of the company's common stock on June 27, 2024, at an average price of $33.68 per share, totaling $1,256,084. Following this transaction, Chapman directly owns 82,234 shares of Insmed. This sale comes as the company continues to d", "url": "https://www.moomoo.com/news/post/72797290/insmed-insider-sold-shares-worth-1256084-according-to-a-recent", "source_name": "Moomoo", "published_at": "2026-07-10T21:09:07", "published_display": "10 Jul 2026 21:09", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INSMED Inc (NASDAQ: INSM) CEO executes 10b5-1 option exercise and sale of 10,699 shares", "summary": "INSMED Inc CEO William Lewis exercised stock options for 10,699 shares and subsequently sold the same number of shares on July 9, 2026, through open-market transactions. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted in September 2025. Lewi", "url": "https://www.stocktitan.net/sec-filings/INSM/form-4-insmed-inc-insider-trading-activity-22882e8a7ad1.html", "source_name": "Stock Titan", "published_at": "2026-07-10T20:09:07", "published_display": "10 Jul 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insmed Slides 4% as Investors Weigh Insider Filing and Near-Term Catalyst Gap", "summary": "Insmed's stock (INSM) dropped 4% following an insider ownership filing and general biotech volatility, as there was no major new operating or clinical update. The filing by Chief Medical Officer Martina Flammer is seen as a potential factor causing de-risking by investors, who ar", "url": "https://www.quiverquant.com/news/Insmed+Slides+4%25+as+Investors+Weigh+Insider+Filing+and+Near-Term+Catalyst+Gap", "source_name": "Quiver Quantitative", "published_at": "2026-07-10T17:37:00", "published_display": "10 Jul 2026 17:37", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INSM Reiterated by Guggenheim -- Price Target Maintained at $207", "summary": "Guggenheim analyst Vamil Divan has reiterated a 'Buy' rating for Insmed (INSM), maintaining a price target of $207.00. GuruFocus indicates the stock is currently undervalued by 32.1% with a GF Value\u2122 of $174.16 against its current price of $118.26. Despite a GF Score\u2122 of 68/100 a", "url": "https://www.gurufocus.com/news/8953480/insm-reiterated-by-guggenheim-price-target-maintained-at-207", "source_name": "GuruFocus", "published_at": "2026-07-10T13:40:28", "published_display": "10 Jul 2026 13:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 INSMED INC For: 9 July By Investing.com", "summary": "This article announces the filing of Form 144 for INSMED INC on July 9, 2026. It highlights the company's stock symbol INSM and its current performance of -3.51%. The content is brief, primarily acting as a notification of the regulatory filing.", "url": "https://ng.investing.com/news/stock-market-news/form-144-insmed-inc-for-9-july-93CH-2593985", "source_name": "Investing.com Nigeria", "published_at": "2026-07-09T22:10:28", "published_display": "09 Jul 2026 22:10", "sentiment": "negative", "sentiment_pct": 39, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insmed Insider Sold Shares Worth $1,352,932, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/insmed-insider-sold-shares-worth-200650425.html", "source_name": "MT Newswires", "published_at": "2026-07-08T20:06:50+00:00", "published_display": "08 Jul 2026 20:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here\u2019s Why TimesSquare Mid Cap Growth Strategy Added Insmed (INSM)", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxNYWNDX1NRWlBDMjNvVW5CeS15X05WVmI2Q0xwY1owckdxVXpsZ1ZEMlh3M1ptTEliV1lMUTNjbzVnV21BenJPTDZNVW1qNE50VGtzaUszN0tKNXU3YnI0bWJoU2hJb09aOHh3UldiTENDRGg0a0dWRTFNd0JVVHBTNVJQTUgxZkVfRzYyOU96ZFQ4Y0ZKbHU2eURBZw?oc=5", "source_name": "Market source", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mizuho Maintains an Outperform Rating on Insmed Incorporated (INSM)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQTUJYUklXTTJhZW5MTFFJVmxXMXlMN2xxZUVTWjM0VEZ1QmlxcGw5SkoxY19aNEFMRE5CMW1sTVNyRk03eVlWSHFMNG1iZmgzWmZCZ3hMT3FLd01SMlBEcWtGeEJiTTN0Tmx6c1JJRmJlZHFhZmIzTnc2TEdXcnlNWEVDWTl0RW9fSzFvODRCamYya29ObjY3VG1XeU5Ja0RSY1pzeQ?oc=5", "source_name": "Market source", "published_at": "2026-06-28T07:00:00+00:00", "published_display": "28 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insmed Insider Sold Shares Worth $2,210,763, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/insmed-insider-sold-shares-worth-200729797.html", "source_name": "MT Newswires", "published_at": "2026-06-26T20:07:29+00:00", "published_display": "26 Jun 2026 20:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INSMED (INSM) CEO Lewis exercises options and sells 21,398 shares under 10b5-1 plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxNTFRWZGM1cGdJMFN1cFE5SWg3UVhSTll0XzRscDVIMUN4SGR4U2pTYldzbG96Ni04bGE2UXk5UDVfQ2pMUHdERnZidG5HdWVsQlotUHVDUzFmTG51c1k3bzkyRVVjWHVnN1pZajRRLWlmWjNqR1FrbFhJXzdHWnRsdEF5QndZTTlXc2NGczRQbXN2OE40Z2R2MVNUTkhkd1N2ZlYybVFDWQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insmed taps Johnson & Johnson veteran to lead its respiratory push", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxONWpVMzdXdFhlaF9JeV8ydmlGS0V2WHZDVERjeHF3X25UZ081ejlheVhCVjlDS3EtME51MzE4Ny1kQU02amczTXV1dXA3aW1kNDAxcExNdURXTDBSWmh6N0JmX2hlcG9tbnhPYkgyQldBLWhlRnVOME40WjBvYkoxVXlLQ05IVHRRMXVjU0c2UUxZem10UERMd2NPOUFvYUFnMk8yaENPMVlHRlN4Y2lSdmg5NjhVQ18xLWc?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insmed Appoints Samuele Butera as Senior Vice President, General Manager, Global Respiratory", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3wFBVV95cUxNYXZxRkNQVWN0djlramdxRUJFZ1pDeTktUUtETWVpMUtyaE9CVWtKOXVmR05FUVZrLTZGb1FkbW1XLTlaazh1U1VCRWZZX3V5d082Z3N0UHhDSndLZkxfVmRfS1RwSFJuNnBzNGo4cDhuOXBlMVlDT0pjUElDdzByS3U5aEJkdXI2dGhkQzBDS0drUG1IdERwOHZBQnhfZFpoUWZ1LTBqMTB5QkwxbHhTNjNlMWZHdldwU3dnblFqQnFVZlh4bEpIVmhJbVZtOWpJVkRncEtoUGlFdE4yRHNn?oc=5", "source_name": "PR Newswire", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insmed: Extensive Phase 3 TPIP Program And Revenue Growth In Q1 2026, Strong Buy", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQaGVNdFNqdzlpcUZDYXRsRmotdHdDeV9fQ21NVTJIeDZtSDBlSmtTMjU1ZWpPTFhfMEVVc3NOOEt0RElfMkV1QjhfeGM1dlowN1hVdGZLQXgtWFJBaEItX1k0QjNDbkdGRmxWbGVJWkVEMFJuWGdFYnBoRUhuYUVPVW82eXU5M0tBbTVTenA5SzNQb1l4YkJYUEVabHprcXRCelpPSm1vdk9xYXY5RGVwNWFmc1B4NHkzM2c?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 95, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Insmed (INSM) One of the Most Promising Healthcare Stocks After Cantor Fitzgerald\u2019s Target Raise?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxOOVA4OGM2ZC00QWNZYjlHY2dUMWNxbU5JS2ljWnZ4dXJHQjFjbTBwMXBTMHlIVWc4aXNmMGZJZTNPTVQ0NGVEN2JER0V1T3c0UG5GUnBhYnZEcVRzNlZBM3hXU2VwbGxzNDd5R3dJYmxvOVdTakU1RUtqUWlJQW84M1Itd09HWk0xUWpZY1RyUm1MWGN3QUE?oc=5", "source_name": "Market source", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insmed (INSM) Remains a Strong Buy Despite Recent Stock Decline", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxOT0F0dUp6SDZadzRjQUJrRUpuT1FvbHQwcm9oTUdXdjZYdTJMVnlMVFdob2g3dHJ1ZElfTmRCZ0FQbE14WV9oR0ZLNlZkTVZYRFlnSGcySlpjcERxQk9Eci1sbHB6X25sWGU3cS03a3ZMeVJtc1NPSGttTGsydVN4bXNXNmE4ZlZQNTZqcGNrVG45dFh2U3l4TjlWLTlRNGdUOHBNZUhEX1MwUUxCckZNUFpxdHRfVFZiamdUdTZVWWxKMlhKV2s4?oc=5", "source_name": "GuruFocus", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Insmed (INSM) The Best Healthcare Stock to Buy Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNUVQwb19RVTVIUjVhbzR5SmpWUWhjWFphWnd6dWFlazk0aUVSX0NmTHdnZzExR290U1F1MzVYUVpLTHcxQlRxWXFVb0JuOVRYd0gtZEhxRDl4VnJUbFRabW91RXVvbEZyMXQ3OXhsUnZQQS1GV08yZnNBZGNDbFNtVlktZXRtcl94STZmUXhmT0ROU2NXMmNtanRrOTh6X0FXMFp4MA?oc=5", "source_name": "Market source", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQZXMwWDdWTldfLUVUMjNqQk84ZVpHTkgwR3hYX3VkS1dCcGpXeHI1WDVXZVREaE1HeEp2b3prbVFKR2lLNktrRmFNd2pWT0RpUHpwNmZER0JobGZrdzB2dmxVY2tvQzF4MjRKX21mbHNLeUpXLVBjbDJ0NTFSUDdTZ09lMzFrSjczbDFsWjkta2hJeUY0X1hsaV82RlRLQU8tT3kydTNya3ZvZw?oc=5", "source_name": "Insmed Incorporated Investor Relations", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Insmed (INSM) Valuation After Recent Share Price Weakness And Brensocatib Launch Expectations", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxOemRrM2VjbzZiLWtkNk11ZzZUQkdZTHpqMEVENXhtcE4yVTdLaVVkS1huMFBmMVpSNnBUbDFmM0JtZElpNU5pbXBRR3Fqc1FFVnJJNnhTMVRzN1lYZFVCTjRlRGZVVlQ2Sjc0QTlFb3pVSGxjei05RUoxeU5YSzJMMTM4Rnd5Nzh6cHE0RThyOG5xVU9VWWRiSEhXSllJbXc?oc=5", "source_name": "Market source", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Insmed (INSM) Valuation After Recent Share Price Pullback And Strong Multi Year Returns", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxPdmwyZzlpVVVaT2g2LU1yVERZcmdkQk5UUkI0cHU1TFJPZ1pyTUpOZXdXaVBoUjljVEpNVmo2Ymk0QThjX29MYVpXYzJPVFZWNHRhRmZrZTVmSlpWanRKZ2xQb0RnakJMNmxINlJzSWVCdjVVemJXZ0E1elViRE4ybVBRZ0JsaXBvbUdlUmxET1pScUZpeEt6ekZqc1YyWDZCWXR0aXlR?oc=5", "source_name": "Market source", "published_at": "2026-05-19T07:00:00+00:00", "published_display": "19 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insmed Shelf Registration Raises Questions On Funding Flexibility And Valuation", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-17T07:00:00+00:00", "published_display": "17 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Insmed stock (US4576693075): Truist cuts price target to $185 on competitive risks", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOc1FWTWRkb2FCR2JacC1rNnhBWGdPeHVrYVpFQm1zY3hPbmMyLXhMZ1R3U0J1QVplQm56MTlfUW14RjJXcHlVRWliRmtBVUgwY2pSYmFSR0ZRUEZnVC1EM0NwSnV4UU4tS2Y0dUk3b0tOZzFYaUczR0dSMmFyMmtZbkhIbmRMZVpyQUkxdU50V0FSMERRbG5hMHg1VjdmM1ltNi1QejVFMVBMMEh5dnB2eGVRMTN0d2o5U0M0?oc=5", "source_name": "ad-hoc-news.de", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Insmed Incorporated (NASDAQ:INSM) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Insmed (INSM) Q1 2026 Revenue Surge Tests Profitability Narrative", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-09T07:00:00+00:00", "published_display": "09 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's What Analysts Are Forecasting For Insmed Incorporated (NASDAQ:INSM) After Its First-Quarter Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxPdS1qVEZLcXZZenRqTFFyb21BcTlHZHVXMVU4UmVwdElNUmpfQ25XNTQ0ek5xYlVmbUtDOGwtWUxzWU5kZnRLSVVnNjhOdU1BcElnTkR5b0hGWVJOdURIYXlkVThyWmNUTjJZVkFtOERBMDNsaVB3QU5wN3ZKN0lpcXppRS1OZmVpRFdDc1Z0cUlucmxzY2RzXzQ3RE9yMHgtbWJURHZfNkx3LXBEVjdOOQ?oc=5", "source_name": "Market source", "published_at": "2026-05-09T07:00:00+00:00", "published_display": "09 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insmed's Q1 Earnings Beat, Sales Miss Estimates, Stock Tanks 23%", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQRF92dXBQWG5zTVBhNXlhQUQ3b0tfYWt1b3JCNDVVSTdJYjhUbV9xRnB0TDgza1BPaTY5OTZ5eUVTV1JEdU5GaDVGVFJtTnNlcmV5YlhRWEE0eGJvbzZWZk5ybmhaWXlxUWI5bGQ5aW04SUNrQkNod2IwZDBrLThlak8zMnVkUDhUZi1WTGRaSG90cWtxa2hFbkNxTTV4Mlpm?oc=5", "source_name": "Market source", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPRWZ0bWpoSnRSbVAyMnAzY2Y2dldVWXRGYnpFUW02VnJvaThjNlFnUmdRcVRJSm9LWXY4WnJjUkZiRWEweEVpWnZZdk1UYzQxVURHc19HeXkyc3g0RDBQd3BHWnA4ZkE1V0tPWWp4VmVNSjhDZWJJZDFjV2tIeHNJNUxCeHZmOU56SV85X0dQdzNyUHVvMTNNd1dFeWgtM1MtcHFOcXZLcXpsOFcxQ3RSUEY3bzNLZVNHcTF3?oc=5", "source_name": "Insmed Incorporated Investor Relations", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insmed pairs new lung-disease data with U.S. diagnosis grant", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxORUFqTUJqbDByeGE5eWZvYktxVnpZc1VJcjJaQkotWXdsODZYN2lURFotX0pMbTZjeGowVGNCWmlCR19NcVhiRWJxU2VKTnpiaGpkV0xCMGE0aHBzVU9kekxyYXBSZkR4MHVuWUZTdXlYY2h3cVhxYTdVcjBlMVBocWd0c0RrYUd5WEUta1U0UVZkblZMVmlTb2x5THJlQWE3N3BQZVBkZWZfb2hTRWVjSWZLbmJfb1NwQ0ZZeQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Time To Reassess Insmed (INSM) After The Recent Share Price Pullback", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-03T07:00:00+00:00", "published_display": "03 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insmed executives line up two healthcare investor conference talks in May", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPZF95SXFtcnJEaUlZSmQ4cmt4V0lPa21UOWw5X18yTEVpcXN5dmowYU1zLXBaWVo0RTdTSmtBN2hyQnpvaWdzMG42M3duOEhWZ3p0UVg4dkRMOExZVjMtQktaZ3M4aHVGSnNWbDFpYWxnSDVnWXFiaHZpanlON1prZlpPdDFCWHZhNlU1WDRseGVvWmFiUGJIQw?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Here Are Friday\u2019s Top Wall Street Analyst Research Calls: Autodesk, Delek US Holdings, Insmed, Nike, Nutanix, ServiceNow, Shake Shack, Southern Copper, Veeva Systems, and More", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgJBVV95cUxQSFVjc2VFZ1VSbWNGTHBVd3YxUlFOY3luVXZmQzRseWk2cWhkX21kWWFDZlM4Nkktdjd2SkRWbmVzb2RDbTAzOXJvZ0hZTExkUVRkVldHZGdMYUlsVmFXWHg0VFZ4c1FMbXFWZlNwOEZRYTBjc1BEUHg0VFgwa19TbE5SSGFkWWdoM1RGb2FLbFk4SlczRUUyTV9USVVic0NRVHExNVA1Y0MwTlM1NV9iaVFQSmxjOU9tbk5ZWTlOYjR6Q21tLTItWmQ5X3Y4R3UzSDJKMkU3QTlaTlFEc0hPSjNpYWp3WFhFRk11aTI0V0IxY3VHV095VnJWdmtxbGhkVU1BLWs5c1dZb19rSWY5Q0c5Wl9hcmpseWM3YWgyZFJ5b0gwSjlteGFRZWo3Vk1QWGc?oc=5", "source_name": "24/7 Wall St.", "published_at": "2026-04-10T07:00:00+00:00", "published_display": "10 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insmed (INSM) Soars 5.5%: Is Further Upside Left in the Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxNSFUta0JJTkhFSHBaLXdCZVNjR1VGWXJTT3NLSlliSUlsSEhzY1ZoanlVUFFSNXJhTDZtR3VnVlpfdF9tWFV1VHZpX0xKbERxdHFCUFRfRzBmMnJZTVhJLWNGOGo3LTVxdk44dlNmN1NlUUNPV3RBOHlSbzNUSHhnSGk1VG54emJRejZ0QjVsRQ?oc=5", "source_name": "Market source", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Insmed CEO reveals Japan patient population exceeds US market for lung disease", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOc2pIQkI5b091dUpPR1RyMnVldmRMMWRIa1NmUWVIZGx5eEVlSzJ6YlI2akxjZmUxQWhUb09vU1JFMzBqb1h4VHNQOXhlWDdRNmFXQ2preDE5TmgybmxpMUhNQmNUaXRsbXNwSzljRUxrYmp0bHhwQ1ROclBtV2g0MC02M3IxQ21jZmNya2hZaE4xLXR2ZmdOeTducE14N3I4Q0l5Q3N3MmpaRUE1QlVJeGRuMFNuMnZxZ3pGNlU1cw?oc=5", "source_name": "24/7 Wall St.", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trade Alert: Independent Director Of Insmed Leo Lee Has Sold Stock", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-21T08:00:00+00:00", "published_display": "21 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insmed Stock Rise on EU Nod for Lung Disease Drug, Brinsupri", "summary": "", "url": "https://news.google.com/rss/articles/CBMiekFVX3lxTE5zbjZqbmtkZ3lNNHRHalNnWWM3a0tWbzRiNGcySDVMNko4eDU0NWZrR00xRHlEQ0lDVlIyR3hKVFNPaXgzdTM2b3ZrUHVibUtCUENUbU9HUnhrSmh0cWYzU0Rqc3cweE0wc3hDQ1U3bkRYbW9BellJUUtR?oc=5", "source_name": "Market source", "published_at": "2025-11-19T08:00:00+00:00", "published_display": "19 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Is Insmed (INSM) Undervalued After Positive TPIP Data Backed A Phase 3 Push?", "summary": "Insmed (INSM) shares are in focus following positive 12-month data from an open-label extension study for treprostinil palmitil inhalation powder in pulmonary arterial hypertension. Despite recent share price volatility, analysts suggest Insmed is significantly undervalued, with ", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-insm/insmed/news/is-insmed-insm-undervalued-after-positive-tpip-data-backed-a/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-20T02:11:22", "published_display": "20 Jul 2026 02:11", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insmed (INSM) Reports 12 Month TPIP Data That Sets Up Phase 3", "summary": "Insmed has reported positive 12-month open-label extension data for TPIP in pulmonary arterial hypertension, showing sustained improvements in clinical endpoints with no new safety signals. These results pave the way for a Phase 3 randomized, controlled trial, providing a new dat", "url": "https://www.webull.com/news/15249917983138816", "source_name": "Webull", "published_at": "2026-07-19T08:11:22", "published_display": "19 Jul 2026 08:11", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Quick Look at Today's Ratings for Insmed(INSM.US), With a Forecast Between $161 to $237", "summary": "This article provides an overview of recent analyst ratings for Insmed (INSM.US), highlighting a consensus price target range of $161 to $237. It outlines the bullish sentiment surrounding the stock based on these expert evaluations. The information suggests a positive outlook fo", "url": "https://www.moomoo.com/news/post/73147296/a-quick-look-at-today-s-ratings-for-insmed-insmus", "source_name": "Moomoo", "published_at": "2026-07-17T15:39:37", "published_display": "17 Jul 2026 15:39", "sentiment": "positive", "sentiment_pct": 76, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insmed stock price target maintained at $200 by Stifel on trial data", "summary": "Stifel reiterated a Buy rating and a $200 price target for Insmed (NASDAQ:INSM) after the company released 12-month open-label extension data from its Phase 2b trial for TPIP, a pulmonary arterial hypertension treatment candidate. The data showed continued clinical benefit and re", "url": "https://www.investing.com/news/analyst-ratings/insmed-stock-price-target-maintained-at-200-by-stifel-on-trial-data-93CH-4798328", "source_name": "Investing.com", "published_at": "2026-07-17T12:10:44", "published_display": "17 Jul 2026 12:10", "sentiment": "positive", "sentiment_pct": 76, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insmed moves closer to $6B opportunity as PAH drug shows long-term durability", "summary": "Insmed's investigational pulmonary arterial hypertension (PAH) drug, treprostinil palmitil inhalation powder (TPIP), demonstrated \"impressive\" long-term efficacy and biomarker improvements in an open-label extension study. Guggenheim Partners projects peak TPIP sales to exceed $6", "url": "https://www.biospace.com/drug-development/insmed-moves-closer-to-6b-opportunity-as-pah-drug-shows-long-term-durability", "source_name": "BioSpace", "published_at": "2026-07-17T12:10:44", "published_display": "17 Jul 2026 12:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insmed Says Treprostinil Shows Sustained Benefit to Pulmonary Arterial Hypertension Patients", "summary": "Insmed announced that data from their Phase 1 TREMOLOTM and Phase 2 BEATTM studies indicate that treprostinil showed sustained benefits for pulmonary arterial hypertension (PAH) patients. The data suggests that the drug could improve pulmonary vascular hemodynamics, functional ca", "url": "https://www.moomoo.com/news/post/73074851/insmed-says-treprostinil-shows-sustained-benefit-to-pulmonary-arterial-hypertension", "source_name": "Moomoo", "published_at": "2026-07-17T08:11:22", "published_display": "17 Jul 2026 08:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insmed reports 12-month TPIP data in pulmonary arterial hypertension", "summary": "Insmed has released positive 12-month data from an ongoing open-label extension study of treprostinil palmitil inhalation powder (TPIP) for pulmonary arterial hypertension (PAH). The data showed sustained improvements in functional, biomarker, and risk-status measures in PAH pati", "url": "https://www.biospectrumasia.com/news/89/28051/insmed-reports-12-month-tpip-data-in-pulmonary-arterial-hypertension.html", "source_name": "BioSpectrum Asia", "published_at": "2026-07-17T08:10:44", "published_display": "17 Jul 2026 08:10", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insmed Incorporated (INSM) Discusses 12-Month Results From Ongoing TPIP Open-Label Extension Study in PAH Patients - Slideshow (NASDAQ:INSM)", "summary": "Insmed Incorporated (INSM) has released a slide deck detailing the 12-month results from its ongoing open-label extension study of TPIP in patients with Pulmonary Arterial Hypertension (PAH). This information was published in conjunction with an event. The study's findings are pr", "url": "https://seekingalpha.com/article/4922780-insmed-incorporated-insm-discusses-12-month-results-from-ongoing-tpip-open-label-extension", "source_name": "Seeking Alpha", "published_at": "2026-07-16T20:27:00", "published_display": "16 Jul 2026 20:27", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insmed Announces Positive 12-Month Data from the Ongoing Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Patients with Pulmonary Arterial Hypertension", "summary": "Insmed announced positive 12-month data from its open-label extension study of treprostinil palmitil inhalation powder (TPIP) for pulmonary arterial hypertension (PAH). The data showed sustained improvement in efficacy measures, including a reduction in mortality risk, and TPIP w", "url": "https://investor.insmed.com/2026-07-16-Insmed-Announces-Positive-12-Month-Data-from-the-Ongoing-Open-Label-Extension-Study-of-Treprostinil-Palmitil-Inhalation-Powder-TPIP-in-Patients-with-Pulmonary-Arterial-Hypertension", "source_name": "Insmed Incorporated Investor Relations", "published_at": "2026-07-16T19:10:44", "published_display": "16 Jul 2026 19:10", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insmed's TPIP Shows Durable PAH Benefits in 12-Month Study", "summary": "", "url": "https://finance.yahoo.com/m/3ab1f69d-9a5a-3c69-98ca-513a4db1c11c/insmed%27s-tpip-shows-durable.html", "source_name": "MarketBeat", "published_at": "2026-07-16T15:04:50+00:00", "published_display": "16 Jul 2026 15:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insmed reports 12-month data for PAH treatment candidate", "summary": "Insmed (NASDAQ:INSM) announced positive 12-month open-label extension study data for its treprostinil palmitil inhalation powder (TPIP) in patients with pulmonary arterial hypertension (PAH). Patients showed significant improvement in six-minute walk distance and decreased NT-pro", "url": "https://www.investing.com/news/company-news/insmed-reports-12month-data-for-pah-treatment-candidate-93CH-4795424", "source_name": "Investing.com", "published_at": "2026-07-16T11:42:31", "published_display": "16 Jul 2026 11:42", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insmed reports positive 12-month OLE results for TPIP showing sustained 6MWD, ~60% NT-proBNP drop", "summary": "Insmed announced positive 12-month Open-Label Extension (OLE) results for TPIP, demonstrating sustained efficacy and good tolerability. The study showed a mean 6MWD improvement in both continued and placebo-crossed groups, aligning by Month 12, along with a significant ~60% drop ", "url": "https://www.tradingview.com/news/tradingview:7718dcb8df0c2:0-insmed-reports-positive-12-month-ole-results-for-tpip-showing-sustained-6mwd-60-nt-probnp-drop/", "source_name": "TradingView", "published_at": "2026-07-16T10:42:31", "published_display": "16 Jul 2026 10:42", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "William Haggerty Joins Insmed Incorporated as Senior Director of People Operations", "summary": "Insmed Incorporated has appointed William Haggerty as Senior Director of People Operations. With over two decades of experience in HR transformation, talent strategy, and AI-enabled workforce innovation, Haggerty previously served at IBM where he spearheaded AI-powered talent ini", "url": "https://hrtoday.in/william-haggerty-joins-insmed-incorporated-as-senior-director-of-people-operations/", "source_name": "https://hrtoday.in/", "published_at": "2026-07-14T17:35:56", "published_display": "14 Jul 2026 17:35", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insmed (INSM) After Insider Selling And Brensocatib Hopes What Does Valuation Say", "summary": "Insmed (INSM) is under scrutiny after its Chair and CEO sold shares following the exercise of stock options. Despite a year-to-date share price drop, longer-term holders have seen significant gains. The article explores Insmed's valuation, highlighting a narrative suggesting it's", "url": "https://www.sahmcapital.com/news/content/insmed-insm-after-insider-selling-and-brensocatib-hopes-what-does-valuation-say-2026-07-13", "source_name": "Sahm", "published_at": "2026-07-13T18:39:56", "published_display": "13 Jul 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Insmed Incorporated \u2013 BMV:INSM", "summary": "This article provides financial data for Insmed Incorporated (BMV:INSM), focusing on its enterprise value to EBIT forward. It displays the company's financial overview on TradingView, indicating that the market was closed at the time of publication with no trades. The content pri", "url": "https://www.tradingview.com/symbols/BMV-INSM/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-12T08:41:21", "published_display": "12 Jul 2026 08:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Insmed Inc For: 10 July By Investing.com", "summary": "This article from Investing.com reports on a Form 4 filing for Insmed Inc. The filing was made on July 10, 2026. The article primarily consists of financial market data and navigation, with the core content being the brief announcement of the Form 4.", "url": "https://za.investing.com/news/stock-market-news/form-4-insmed-inc-for-10-july-93CH-4364859", "source_name": "Investing.com South Africa", "published_at": "2026-07-10T21:09:51", "published_display": "10 Jul 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insmed CEO William Lewis sells over $1.25m in company stock", "summary": "Insmed CEO William Lewis sold 10,699 shares of the company's common stock for over $1.25 million on July 9, 2026, while concurrently acquiring the same number of shares through stock option exercises. These transactions were executed under a Rule 10b5-1 trading plan. The company'", "url": "https://ng.investing.com/news/stock-market-news/insmed-ceo-william-lewis-sells-over-125m-in-company-stock-93CH-2595435", "source_name": "Investing.com Nigeria", "published_at": "2026-07-10T21:09:51", "published_display": "10 Jul 2026 21:09", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insmed Insider Sold Shares Worth $1,256,084, According to a Recent SEC Filing", "summary": "Insmed insider Paul C. Chapman sold 37,294 shares of the company's common stock on June 27, 2024, at an average price of $33.68 per share, totaling $1,256,084. Following this transaction, Chapman directly owns 82,234 shares of Insmed. This sale comes as the company continues to d", "url": "https://www.moomoo.com/news/post/72797290/insmed-insider-sold-shares-worth-1256084-according-to-a-recent", "source_name": "Moomoo", "published_at": "2026-07-10T21:09:07", "published_display": "10 Jul 2026 21:09", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INSMED Inc (NASDAQ: INSM) CEO executes 10b5-1 option exercise and sale of 10,699 shares", "summary": "INSMED Inc CEO William Lewis exercised stock options for 10,699 shares and subsequently sold the same number of shares on July 9, 2026, through open-market transactions. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted in September 2025. Lewi", "url": "https://www.stocktitan.net/sec-filings/INSM/form-4-insmed-inc-insider-trading-activity-22882e8a7ad1.html", "source_name": "Stock Titan", "published_at": "2026-07-10T20:09:07", "published_display": "10 Jul 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insmed Slides 4% as Investors Weigh Insider Filing and Near-Term Catalyst Gap", "summary": "Insmed's stock (INSM) dropped 4% following an insider ownership filing and general biotech volatility, as there was no major new operating or clinical update. The filing by Chief Medical Officer Martina Flammer is seen as a potential factor causing de-risking by investors, who ar", "url": "https://www.quiverquant.com/news/Insmed+Slides+4%25+as+Investors+Weigh+Insider+Filing+and+Near-Term+Catalyst+Gap", "source_name": "Quiver Quantitative", "published_at": "2026-07-10T17:37:00", "published_display": "10 Jul 2026 17:37", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INSM Reiterated by Guggenheim -- Price Target Maintained at $207", "summary": "Guggenheim analyst Vamil Divan has reiterated a 'Buy' rating for Insmed (INSM), maintaining a price target of $207.00. GuruFocus indicates the stock is currently undervalued by 32.1% with a GF Value\u2122 of $174.16 against its current price of $118.26. Despite a GF Score\u2122 of 68/100 a", "url": "https://www.gurufocus.com/news/8953480/insm-reiterated-by-guggenheim-price-target-maintained-at-207", "source_name": "GuruFocus", "published_at": "2026-07-10T13:40:28", "published_display": "10 Jul 2026 13:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 INSMED INC For: 9 July By Investing.com", "summary": "This article announces the filing of Form 144 for INSMED INC on July 9, 2026. It highlights the company's stock symbol INSM and its current performance of -3.51%. The content is brief, primarily acting as a notification of the regulatory filing.", "url": "https://ng.investing.com/news/stock-market-news/form-144-insmed-inc-for-9-july-93CH-2593985", "source_name": "Investing.com Nigeria", "published_at": "2026-07-09T22:10:28", "published_display": "09 Jul 2026 22:10", "sentiment": "negative", "sentiment_pct": 39, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insmed Insider Sold Shares Worth $1,352,932, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/insmed-insider-sold-shares-worth-200650425.html", "source_name": "MT Newswires", "published_at": "2026-07-08T20:06:50+00:00", "published_display": "08 Jul 2026 20:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here\u2019s Why TimesSquare Mid Cap Growth Strategy Added Insmed (INSM)", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxNYWNDX1NRWlBDMjNvVW5CeS15X05WVmI2Q0xwY1owckdxVXpsZ1ZEMlh3M1ptTEliV1lMUTNjbzVnV21BenJPTDZNVW1qNE50VGtzaUszN0tKNXU3YnI0bWJoU2hJb09aOHh3UldiTENDRGg0a0dWRTFNd0JVVHBTNVJQTUgxZkVfRzYyOU96ZFQ4Y0ZKbHU2eURBZw?oc=5", "source_name": "Market source", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mizuho Maintains an Outperform Rating on Insmed Incorporated (INSM)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQTUJYUklXTTJhZW5MTFFJVmxXMXlMN2xxZUVTWjM0VEZ1QmlxcGw5SkoxY19aNEFMRE5CMW1sTVNyRk03eVlWSHFMNG1iZmgzWmZCZ3hMT3FLd01SMlBEcWtGeEJiTTN0Tmx6c1JJRmJlZHFhZmIzTnc2TEdXcnlNWEVDWTl0RW9fSzFvODRCamYya29ObjY3VG1XeU5Ja0RSY1pzeQ?oc=5", "source_name": "Market source", "published_at": "2026-06-28T07:00:00+00:00", "published_display": "28 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insmed Insider Sold Shares Worth $2,210,763, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/insmed-insider-sold-shares-worth-200729797.html", "source_name": "MT Newswires", "published_at": "2026-06-26T20:07:29+00:00", "published_display": "26 Jun 2026 20:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INSMED (INSM) CEO Lewis exercises options and sells 21,398 shares under 10b5-1 plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxNTFRWZGM1cGdJMFN1cFE5SWg3UVhSTll0XzRscDVIMUN4SGR4U2pTYldzbG96Ni04bGE2UXk5UDVfQ2pMUHdERnZidG5HdWVsQlotUHVDUzFmTG51c1k3bzkyRVVjWHVnN1pZajRRLWlmWjNqR1FrbFhJXzdHWnRsdEF5QndZTTlXc2NGczRQbXN2OE40Z2R2MVNUTkhkd1N2ZlYybVFDWQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insmed taps Johnson & Johnson veteran to lead its respiratory push", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxONWpVMzdXdFhlaF9JeV8ydmlGS0V2WHZDVERjeHF3X25UZ081ejlheVhCVjlDS3EtME51MzE4Ny1kQU02amczTXV1dXA3aW1kNDAxcExNdURXTDBSWmh6N0JmX2hlcG9tbnhPYkgyQldBLWhlRnVOME40WjBvYkoxVXlLQ05IVHRRMXVjU0c2UUxZem10UERMd2NPOUFvYUFnMk8yaENPMVlHRlN4Y2lSdmg5NjhVQ18xLWc?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insmed Appoints Samuele Butera as Senior Vice President, General Manager, Global Respiratory", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3wFBVV95cUxNYXZxRkNQVWN0djlramdxRUJFZ1pDeTktUUtETWVpMUtyaE9CVWtKOXVmR05FUVZrLTZGb1FkbW1XLTlaazh1U1VCRWZZX3V5d082Z3N0UHhDSndLZkxfVmRfS1RwSFJuNnBzNGo4cDhuOXBlMVlDT0pjUElDdzByS3U5aEJkdXI2dGhkQzBDS0drUG1IdERwOHZBQnhfZFpoUWZ1LTBqMTB5QkwxbHhTNjNlMWZHdldwU3dnblFqQnFVZlh4bEpIVmhJbVZtOWpJVkRncEtoUGlFdE4yRHNn?oc=5", "source_name": "PR Newswire", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insmed: Extensive Phase 3 TPIP Program And Revenue Growth In Q1 2026, Strong Buy", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQaGVNdFNqdzlpcUZDYXRsRmotdHdDeV9fQ21NVTJIeDZtSDBlSmtTMjU1ZWpPTFhfMEVVc3NOOEt0RElfMkV1QjhfeGM1dlowN1hVdGZLQXgtWFJBaEItX1k0QjNDbkdGRmxWbGVJWkVEMFJuWGdFYnBoRUhuYUVPVW82eXU5M0tBbTVTenA5SzNQb1l4YkJYUEVabHprcXRCelpPSm1vdk9xYXY5RGVwNWFmc1B4NHkzM2c?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 95, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Insmed (INSM) One of the Most Promising Healthcare Stocks After Cantor Fitzgerald\u2019s Target Raise?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxOOVA4OGM2ZC00QWNZYjlHY2dUMWNxbU5JS2ljWnZ4dXJHQjFjbTBwMXBTMHlIVWc4aXNmMGZJZTNPTVQ0NGVEN2JER0V1T3c0UG5GUnBhYnZEcVRzNlZBM3hXU2VwbGxzNDd5R3dJYmxvOVdTakU1RUtqUWlJQW84M1Itd09HWk0xUWpZY1RyUm1MWGN3QUE?oc=5", "source_name": "Market source", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insmed (INSM) Remains a Strong Buy Despite Recent Stock Decline", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxOT0F0dUp6SDZadzRjQUJrRUpuT1FvbHQwcm9oTUdXdjZYdTJMVnlMVFdob2g3dHJ1ZElfTmRCZ0FQbE14WV9oR0ZLNlZkTVZYRFlnSGcySlpjcERxQk9Eci1sbHB6X25sWGU3cS03a3ZMeVJtc1NPSGttTGsydVN4bXNXNmE4ZlZQNTZqcGNrVG45dFh2U3l4TjlWLTlRNGdUOHBNZUhEX1MwUUxCckZNUFpxdHRfVFZiamdUdTZVWWxKMlhKV2s4?oc=5", "source_name": "GuruFocus", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Insmed (INSM) The Best Healthcare Stock to Buy Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNUVQwb19RVTVIUjVhbzR5SmpWUWhjWFphWnd6dWFlazk0aUVSX0NmTHdnZzExR290U1F1MzVYUVpLTHcxQlRxWXFVb0JuOVRYd0gtZEhxRDl4VnJUbFRabW91RXVvbEZyMXQ3OXhsUnZQQS1GV08yZnNBZGNDbFNtVlktZXRtcl94STZmUXhmT0ROU2NXMmNtanRrOTh6X0FXMFp4MA?oc=5", "source_name": "Market source", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQZXMwWDdWTldfLUVUMjNqQk84ZVpHTkgwR3hYX3VkS1dCcGpXeHI1WDVXZVREaE1HeEp2b3prbVFKR2lLNktrRmFNd2pWT0RpUHpwNmZER0JobGZrdzB2dmxVY2tvQzF4MjRKX21mbHNLeUpXLVBjbDJ0NTFSUDdTZ09lMzFrSjczbDFsWjkta2hJeUY0X1hsaV82RlRLQU8tT3kydTNya3ZvZw?oc=5", "source_name": "Insmed Incorporated Investor Relations", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Insmed (INSM) Valuation After Recent Share Price Weakness And Brensocatib Launch Expectations", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxOemRrM2VjbzZiLWtkNk11ZzZUQkdZTHpqMEVENXhtcE4yVTdLaVVkS1huMFBmMVpSNnBUbDFmM0JtZElpNU5pbXBRR3Fqc1FFVnJJNnhTMVRzN1lYZFVCTjRlRGZVVlQ2Sjc0QTlFb3pVSGxjei05RUoxeU5YSzJMMTM4Rnd5Nzh6cHE0RThyOG5xVU9VWWRiSEhXSllJbXc?oc=5", "source_name": "Market source", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Insmed (INSM) Valuation After Recent Share Price Pullback And Strong Multi Year Returns", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxPdmwyZzlpVVVaT2g2LU1yVERZcmdkQk5UUkI0cHU1TFJPZ1pyTUpOZXdXaVBoUjljVEpNVmo2Ymk0QThjX29MYVpXYzJPVFZWNHRhRmZrZTVmSlpWanRKZ2xQb0RnakJMNmxINlJzSWVCdjVVemJXZ0E1elViRE4ybVBRZ0JsaXBvbUdlUmxET1pScUZpeEt6ekZqc1YyWDZCWXR0aXlR?oc=5", "source_name": "Market source", "published_at": "2026-05-19T07:00:00+00:00", "published_display": "19 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insmed Shelf Registration Raises Questions On Funding Flexibility And Valuation", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-17T07:00:00+00:00", "published_display": "17 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insmed stock (US4576693075): Truist cuts price target to $185 on competitive risks", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOc1FWTWRkb2FCR2JacC1rNnhBWGdPeHVrYVpFQm1zY3hPbmMyLXhMZ1R3U0J1QVplQm56MTlfUW14RjJXcHlVRWliRmtBVUgwY2pSYmFSR0ZRUEZnVC1EM0NwSnV4UU4tS2Y0dUk3b0tOZzFYaUczR0dSMmFyMmtZbkhIbmRMZVpyQUkxdU50V0FSMERRbG5hMHg1VjdmM1ltNi1QejVFMVBMMEh5dnB2eGVRMTN0d2o5U0M0?oc=5", "source_name": "ad-hoc-news.de", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insmed Incorporated (NASDAQ:INSM) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxQNFJiQXZrbmVkTXNiNnQ2LWN1MGhYdk51Vm5NcHRjSTNmNklfVHYxM3JaSUNQY1BxTWpsT04zS0swcnE2MmZNdkNNS09GSERhMlNCXy13US00ZV9iekYyTmpmTEx2ckN1bFVmd1ZaSXl6VEttUV9acTRjOTdPdnFxelo1ZFJKTWVnQVJ6RGhqYXhpXzdOMmZHdXpvNnY4ZXh6LW1LTmkyc21GekZna1JzZUo2dEtqZGYtQm1Hc3k0eFdXMGVzbmpQZDdoZ1BwdTNLb2ZKRGRIRdIB3AFBVV95cUxOMU5jUERPNURqYVJMbGl0WVpndWdWWUhkQTdHU1lSRDRPeU1sVGhRa0FWRnFwMHdIOEtJam5ZME5DUzloUjhXVWJUR0ZieUg1cGxIc3otNmRyeW0wV2liU3pPSFdjRDh5YUFTR2ZhdE9NM1VCV0tQMk1fRDVrNF9EcGtKRHFuNTRfMTNKU0t5MXNGRU5kYi0xWWVUa25TUEc2M1VPMnVWR3pINy1sQ0F2YTkwQ1Y1LXhVVE1DdC1GbE5vYU9SdnNVeTU4X0wtcElpNzZybnVsZk1BbGhr?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insmed (INSM) Q1 2026 Revenue Surge Tests Profitability Narrative", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-09T07:00:00+00:00", "published_display": "09 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's What Analysts Are Forecasting For Insmed Incorporated (NASDAQ:INSM) After Its First-Quarter Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxPdS1qVEZLcXZZenRqTFFyb21BcTlHZHVXMVU4UmVwdElNUmpfQ25XNTQ0ek5xYlVmbUtDOGwtWUxzWU5kZnRLSVVnNjhOdU1BcElnTkR5b0hGWVJOdURIYXlkVThyWmNUTjJZVkFtOERBMDNsaVB3QU5wN3ZKN0lpcXppRS1OZmVpRFdDc1Z0cUlucmxzY2RzXzQ3RE9yMHgtbWJURHZfNkx3LXBEVjdOOQ?oc=5", "source_name": "Market source", "published_at": "2026-05-09T07:00:00+00:00", "published_display": "09 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insmed's Q1 Earnings Beat, Sales Miss Estimates, Stock Tanks 23%", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQRF92dXBQWG5zTVBhNXlhQUQ3b0tfYWt1b3JCNDVVSTdJYjhUbV9xRnB0TDgza1BPaTY5OTZ5eUVTV1JEdU5GaDVGVFJtTnNlcmV5YlhRWEE0eGJvbzZWZk5ybmhaWXlxUWI5bGQ5aW04SUNrQkNod2IwZDBrLThlak8zMnVkUDhUZi1WTGRaSG90cWtxa2hFbkNxTTV4Mlpm?oc=5", "source_name": "Market source", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPRWZ0bWpoSnRSbVAyMnAzY2Y2dldVWXRGYnpFUW02VnJvaThjNlFnUmdRcVRJSm9LWXY4WnJjUkZiRWEweEVpWnZZdk1UYzQxVURHc19HeXkyc3g0RDBQd3BHWnA4ZkE1V0tPWWp4VmVNSjhDZWJJZDFjV2tIeHNJNUxCeHZmOU56SV85X0dQdzNyUHVvMTNNd1dFeWgtM1MtcHFOcXZLcXpsOFcxQ3RSUEY3bzNLZVNHcTF3?oc=5", "source_name": "Insmed Incorporated Investor Relations", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insmed pairs new lung-disease data with U.S. diagnosis grant", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxORUFqTUJqbDByeGE5eWZvYktxVnpZc1VJcjJaQkotWXdsODZYN2lURFotX0pMbTZjeGowVGNCWmlCR19NcVhiRWJxU2VKTnpiaGpkV0xCMGE0aHBzVU9kekxyYXBSZkR4MHVuWUZTdXlYY2h3cVhxYTdVcjBlMVBocWd0c0RrYUd5WEUta1U0UVZkblZMVmlTb2x5THJlQWE3N3BQZVBkZWZfb2hTRWVjSWZLbmJfb1NwQ0ZZeQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Time To Reassess Insmed (INSM) After The Recent Share Price Pullback", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-03T07:00:00+00:00", "published_display": "03 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insmed executives line up two healthcare investor conference talks in May", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPZF95SXFtcnJEaUlZSmQ4cmt4V0lPa21UOWw5X18yTEVpcXN5dmowYU1zLXBaWVo0RTdTSmtBN2hyQnpvaWdzMG42M3duOEhWZ3p0UVg4dkRMOExZVjMtQktaZ3M4aHVGSnNWbDFpYWxnSDVnWXFiaHZpanlON1prZlpPdDFCWHZhNlU1WDRseGVvWmFiUGJIQw?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here Are Friday\u2019s Top Wall Street Analyst Research Calls: Autodesk, Delek US Holdings, Insmed, Nike, Nutanix, ServiceNow, Shake Shack, Southern Copper, Veeva Systems, and More", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgJBVV95cUxQSFVjc2VFZ1VSbWNGTHBVd3YxUlFOY3luVXZmQzRseWk2cWhkX21kWWFDZlM4Nkktdjd2SkRWbmVzb2RDbTAzOXJvZ0hZTExkUVRkVldHZGdMYUlsVmFXWHg0VFZ4c1FMbXFWZlNwOEZRYTBjc1BEUHg0VFgwa19TbE5SSGFkWWdoM1RGb2FLbFk4SlczRUUyTV9USVVic0NRVHExNVA1Y0MwTlM1NV9iaVFQSmxjOU9tbk5ZWTlOYjR6Q21tLTItWmQ5X3Y4R3UzSDJKMkU3QTlaTlFEc0hPSjNpYWp3WFhFRk11aTI0V0IxY3VHV095VnJWdmtxbGhkVU1BLWs5c1dZb19rSWY5Q0c5Wl9hcmpseWM3YWgyZFJ5b0gwSjlteGFRZWo3Vk1QWGc?oc=5", "source_name": "24/7 Wall St.", "published_at": "2026-04-10T07:00:00+00:00", "published_display": "10 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insmed (INSM) Soars 5.5%: Is Further Upside Left in the Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxNSFUta0JJTkhFSHBaLXdCZVNjR1VGWXJTT3NLSlliSUlsSEhzY1ZoanlVUFFSNXJhTDZtR3VnVlpfdF9tWFV1VHZpX0xKbERxdHFCUFRfRzBmMnJZTVhJLWNGOGo3LTVxdk44dlNmN1NlUUNPV3RBOHlSbzNUSHhnSGk1VG54emJRejZ0QjVsRQ?oc=5", "source_name": "Market source", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insmed CEO reveals Japan patient population exceeds US market for lung disease", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOc2pIQkI5b091dUpPR1RyMnVldmRMMWRIa1NmUWVIZGx5eEVlSzJ6YlI2akxjZmUxQWhUb09vU1JFMzBqb1h4VHNQOXhlWDdRNmFXQ2preDE5TmgybmxpMUhNQmNUaXRsbXNwSzljRUxrYmp0bHhwQ1ROclBtV2g0MC02M3IxQ21jZmNya2hZaE4xLXR2ZmdOeTducE14N3I4Q0l5Q3N3MmpaRUE1QlVJeGRuMFNuMnZxZ3pGNlU1cw?oc=5", "source_name": "24/7 Wall St.", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trade Alert: Independent Director Of Insmed Leo Lee Has Sold Stock", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-21T08:00:00+00:00", "published_display": "21 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insmed Stock Rise on EU Nod for Lung Disease Drug, Brinsupri", "summary": "", "url": "https://news.google.com/rss/articles/CBMiekFVX3lxTE5zbjZqbmtkZ3lNNHRHalNnWWM3a0tWbzRiNGcySDVMNko4eDU0NWZrR00xRHlEQ0lDVlIyR3hKVFNPaXgzdTM2b3ZrUHVibUtCUENUbU9HUnhrSmh0cWYzU0Rqc3cweE0wc3hDQ1U3bkRYbW9BellJUUtR?oc=5", "source_name": "Market source", "published_at": "2025-11-19T08:00:00+00:00", "published_display": "19 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 101, "total_relevant": 62, "sentiment_summary": {"positive": 25, "negative": 6, "neutral": 31, "score": 58, "total": 62, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 80, "events": [{"event": "general", "label": "Market update", "weight": 18.7, "count": 34}, {"event": "earnings", "label": "Earnings", "weight": 9.91, "count": 19}, {"event": "analyst", "label": "Analyst action", "weight": 3.3, "count": 6}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.1, "count": 2}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 25, "negative_events": 6}, "market_context": {"has_market_context": true, "latest_close": 108.32, "latest_week": "2026-07-17", "one_week_move": -6.3, "four_week_move": 13.1, "twelve_week_move": -19.9, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.837465, "market_dynamics_buy_signal": false, "relative_strength": -33.637373, "fair_value_gap": 28.1, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 52.7137, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-6.3% over one week, +13.1% over four weeks, trend inactive, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 68, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 16}, {"label": "simplywall.st", "count": 7}, {"label": "Stock Titan", "count": 5}, {"label": "Moomoo", "count": 3}, {"label": "Insmed Incorporated Investor Relations", "count": 3}, {"label": "TradingView", "count": 3}, {"label": "Investing.com", "count": 2}, {"label": "Seeking Alpha", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 53}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 34}, {"label": "Earnings", "count": 19}, {"label": "Analyst action", "count": 6}, {"label": "Regulatory and legal", "count": 2}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "58/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "80/100 classification confidence."}, {"label": "Company focus", "value": "53", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-6.3% over one week, +13.1% over four weeks, trend inactive, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Is Insmed (INSM) Undervalued After Positive TPIP Data Backed A Phase 3 Push?"}], "updated_at": "2026-07-20T11:24:32.541747+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}